To date, Cellectis holds sixty patents, its portfolio includes over 260 patents and patent applications pending, including rights acquired with Vectocell® technology. Cellectis is expanding its development by establishing licensing agreements for proprietary technologies and technologies for which it holds the exclusive license:
- Access to its meganuclease engineering platform in the context of collaborative projects to develop new therapeutic programs, cell lines and agricultural traits. This technology will realize the first proof of concept in animals in the coming years. It is already being used in the commercial development of plants and therapeutic proteins.
|
- Access to patents for homologous recombination, to create and use genetically modified cells and mice. This technology is achieving a certain maturity, since it is used globally by the pharmaceutical and Biotechnology industries. It is currently used at different stages, from research into targeted therapies to drug manufacturing. Our intellectual property is providing optimum value for Cellectis, as well as for Institut Pasteur, which owns the parent patents.
|
